Introduction {#Sec1}
============

Most biologicals produced in animal cell culture are continuously synthesized during the cell proliferation phase. Recombinant proteins, for example, are typically produced in batch or fed-batch mode, where the product is accumulated in the culture broth and harvested once peak concentrations are reached (Castilho et al. [@CR3]). In contrast, the production of viral vaccines typically requires a cell growth phase followed by a virus replication phase (both typically operated in batch mode) as most viruses propagate in a complex process that requires the internalization of their genetic material into the host cell, the synthesis of viral RNA/DNA and viral proteins as well as the release of progeny virus particles (Aunins [@CR1]). Furthermore, it has to be taken into account that the replication process of lytic viruses results in cell death due to apoptosis followed by cell degradation and release of contaminants such as cellular DNA and host cell proteins.

To increase virus production yields through process optimization, three key factors need to be considered:Cell concentration and metabolic/physiological status of the cells at time of infection (toi): As a general rule, cell concentration defines final virus titers. However, it is essential to perform infections on healthy cells, with no limitation of key nutrients, not inhibited by accumulated by-products such as lactate and ammonia, and in an appropriate growth status (i.e., dividing/non-dividing, cell cycle phase) (Demarchi and Kaplan [@CR9]).Ratio of infectious particles to viable cells, namely multiplicity of infection (moi) at the time of infection (toi): Since virus transport to the target cell in the culture medium is governed by diffusion, an optimal amount of virus particles per cell should be inoculated to counteract degradation/inactivation of infectious virions before they reach their host cell (Aunins [@CR1]). In addition, for most viruses, a too high number of virus particles per cell at toi can promote replication of so-called defective interfering particles (DIPs), which decreases maximum virus yields. This is of particular importance in continuous cultivations using cascades of stirred tank bioreactors (STR), where decreases in virus titers for long cultivation times have been observed as a consequence of DIP accumulation (Frensing [@CR12]; van Lier et al. [@CR62]).Residence time (RT) of virus particles within the bioreactor and time point of harvest (toh): The RT can be defined as the time that a cell or a virus particle remains inside the bioreactor and is characteristic for the cultivation mode. In closed systems operated in batch cultivation mode, the RT is identical for all particles and equivalent to the harvest time. After having achieved maximum titers, virus infectivity as well as the total number of virus particles can decrease again (Aunins [@CR1]), while the extracellular DNA and protein contamination level can increase significantly due to cell lysis. Accordingly, time of harvest has to be determined carefully, taking into account vaccine type (live attenuated, inactivated) and downstream processing requirements. In particular, for viral vaccines, where potency depends totally or partially on infectivity (e.g., live attenuated vaccines, viral vectors), a short RT/early toh is beneficial. When batch knowledge is transferred to continuous systems, the picture is more complex as not all particles spend the same time inside the continuously operated bioreactor. In continuous bioreactors, an important concept is the RT distribution, which is essentially a statistical approach to describe the probability of particles to leave the bioreactor (Levenspiel [@CR33]; Sarkar et al. [@CR56]). Nevertheless, a good approximation is given by the average RT that, in continuous STRs, equals the inverse of the dilution rate (RT = 1/D).

In order to address the impact of the first key factor (cell concentration, physiological status) on process intensification, approaches towards optimization of upstream processes for manufacturing of other biologicals, i.e., CHO cell-derived recombinant proteins, can serve as a general guideline. Here, high cell density (HCD) processes have been developed for the production of biopharmaceuticals over more than 20 years (Kompala and Ozturk [@CR28]; Ozturk [@CR44], [@CR45]), and a high number of products have been introduced into the market (Kompala and Ozturk [@CR28]; Pollock et al. [@CR49]). Typically, HCD processes rely on fed-batch or perfusion strategies and the use of one or the other depends on specific requirements of the product and technical aspects. However, perfusion bioreactors have the potential to achieve higher cell concentrations since they offer a constant nutrient-enriched environment avoiding the accumulation of unwanted by-products (Fig. [1](#Fig1){ref-type="fig"}a) (Castilho et al. [@CR3]). In addition, these cultivation conditions allow the use of cultivation systems with a low footprint and with high volumetric production rates (Ozturk [@CR44], [@CR45]). For process intensification in viral vaccine production, however, significant differences compared to the classical production process of recombinant proteins exist. Due to the separation of most of the virus production processes in a cell growth phase and a virus replication phase, different production profiles and kinetics are to be expected (Fig. [1](#Fig1){ref-type="fig"}b). In particular, the use of specific process strategies during virus propagation needs to be considered.Fig. 1Schematic representation of the perfusion-based high cell density (HCD) production of recombinant proteins and viruses. **a** Concentration profiles of different performance parameters in a perfused bioreactor for the production of recombinant proteins. **b** Concentration profiles of different performance parameters in a perfused bioreactor for the production of viruses. *V* volume, *X* ~*V*~ cell concentration, *P* recombinant protein concentration, *Vir* virus particle concentration, *S* substrate (glucose) concentration

Regarding the cell retention in perfusion systems, a large variety of examples can be found for the production of recombinant proteins (Pollock et al. [@CR49]). In general, filtration-based systems (i.e., internal and external spin filter, ATF and TFF), gravity settlers, and acoustic filters have been extensively used in the industry as well as in academia (Clincke et al. [@CR4]; Kompala and Ozturk [@CR28]; Pollock et al. [@CR49]). Some of these systems have potential drawbacks such as filter clogging (membrane-based systems) and limited scalability (gravity settlers and acoustic filters). Accordingly, alternating tangential flow (ATF) and tangential flow filtration (TFF) systems have attracted considerable attention since they have a reduced risk of filter clogging (due to the cross-flow filtration) and can be easily scaled up based on the surface area of the hollow fiber cartridge (Kompala and Ozturk [@CR28]). All this allows cultivations to very high cell concentrations in the order of 10^8^ cells/mL (Clincke et al. [@CR4]). Other options for HCD cultivation of animal cells are fixed-bed reactors and entrapping retention systems. These systems, however, are known for heterogeneities regarding the distribution of medium components and gases (de la Broise et al. [@CR8]) as well as for their operational complexity (Kompala and Ozturk [@CR28]). Nevertheless, a recently developed fixed-bed bioreactor (CellTank®, PerfuseCell) has shown homogeneous concentration of metabolites allowing cultivation of CHO K1 cells at concentrations up to 2 × 10^8^ cells/mL (Zhang et al. [@CR72]).

Process yields of viral vaccine manufacturing can also be improved using true continuous systems, i.e., chemostats (Kilburn and van Wezel [@CR27]) or multi-stage systems such as the two-stage bioreactor (Frensing et al. [@CR13]). Continuous bioreactors can operate at steady-state conditions (constant cell and metabolite concentration, pH value, and osmolality) avoiding shutdown times for cleaning and sterilization cycles typical for batch operation (Hoskisson and Hobbs [@CR22]; Konstantinov and Cooney [@CR30]). It was estimated that continuous cultivations can reduce operational costs by up to 55 % compared to batch processes (Walther et al. [@CR68]). Manufacturing of biologicals at steady-state conditions is also assumed to positively influence the quality of the final product as, e.g., more consistent glycoform profiles and reduced protein deamidation can be obtained (Konstantinov and Cooney [@CR30]). If viral vaccines are produced, steady-state operation at optimum virus RT could help to prevent fast degradation of infectious virus particles compared to batch cultivations, being beneficial for production of live-attenuated vaccines or viral vectors such as MVA virus (Jordan et al. [@CR26]). The main problem with the use of true continuous cultivation strategies in viral vaccine production is, however, that it is not clear whether vaccines produced would be acceptable for regulatory agencies such as FDA and EMA as several open questions remain to be answered regarding the long-term genetic stability of cell substrates and virus strains (Gallo-Ramirez et al. [@CR14]). In particular, it has to be investigated in detail, whether undesired viral mutations can accumulate overproduction time that can negatively influence potency and safety of vaccines. Similarly, in continuous systems, moi can increase during cultivation time as a consequence of virus replication and therefore promote excessive production of DIPs as addressed above (Frensing [@CR12]). Finally, there is still little experience regarding more complex aspects of the viral life cycle (i.e., virus latency, lytic stages) on virus yields and on vaccine quality (Kilburn and van Wezel [@CR27]; Roumillat et al. [@CR52]).

In the following, we present a comprehensive overview of options for process intensification in cell culture-based viral vaccine production. In particular, we consider the establishment of HCD cultivations and the use of continuous multi-stage bioreactors. The focus of HCD will be on fed-batch strategies and operation in perfusion mode using ATF systems, hollow fiber bioreactors and acoustic filters as these systems have the highest potential for production of viral vaccines. In addition, process options regarding the use of two- and three-stage continuous bioreactors for virus production are addressed. Literature regarding baculovirus-insect cell expression systems is highlighted here due to its significant contribution to the understanding of virus dynamics in continuous cultures. As very few studies deal with HCD cultivations or continuous production systems in large-scale virus vaccine manufacturing, mainly, results obtained at laboratory scale will be presented for illustration of process options.

Virus production at high cell densities {#Sec2}
=======================================

The term "high cell density" was previously defined as any cell concentration in the order of 10^7^ cells/mL (Griffiths et al. [@CR19]). However, authors have often taken as a reference the typical cell concentrations achieved so far for a reference production process (typically batch) for that specific cell line. For many of the conventional cell lines used in vaccine production, this was in the range of 2 × 10^6^ cells/mL to 4 × 10^6^ cells/mL. Based on that, cell concentrations one order of magnitude higher than those obtained by established cultivation processes have been considered as high cell densities.

Given the nature of most virus propagation processes, where cells are infected at the late exponential growth phase, the cell concentrations need first to be increased to concentrations that cannot be achieved in batch mode for a HCD process. In addition, virus propagation at such high cell concentrations must be performed at the optimal conditions to avoid the so-called cell density effect, which is a reduction in the cell-specific virus yield (Lindsay and Betenbaugh [@CR35]; Maranga et al. [@CR39]). A summary of HCD virus production processes and their main characteristics is given in Table [1](#Tab1){ref-type="table"}.Table 1Overview on viruses produced in high cell density cultures reported in literatureVirusCell lineTypeMaximum cell concentrations (×10^6^ cell/mL)Bioreactor typeCell proliferationVirus infection/propagationVirus harvest during propagationHighest yieldsCommentsReferenceAdenovirusHEK293Suspension8STR/TFFPerfusionHalting/perfusionNo7.8 × 10^9^ IVP/mL at 35 °C5.5 times higher than the batch control in spinner flaskCortin et al. [@CR5]Adenovirus ONYX-411 (recombinant oncolytic vector)HeLaS3 human tumor cellSuspension14.8STR/TFFPerfusionHalting/perfusionNo (intracellular viral vectors)6 × 10^11^ VP/mLTiter sevenfolds higher than those achieved in fed-batchYuk et al. [@CR71]Adenovirus type 5HEK293Suspension3STR/acoustic settlerPerfusionPerfusionNo (intracellular viral vectors, high MOI = 20 at infection)16,200 VP/cell 6.0 × 10^9^ VP/mLCell-specific and volumetric yields comparable to batch. However, infection at a cell density of 6 × 10^6^ cells/mL led to a fivefold reduction in specific productivityHenry et al. [@CR20]Adenovirus type 5HEK293Suspension7.8STR/TFFPerfusionHalting/perfusionNo4.4 × 10^10^ IVP/mL 5600 IVP/cellCell-specific yield 4.3 times higher than batchGálvez et al. [@CR15]Adenovirus type 5, 26, 35PER.C6Suspension16STR/TFFPerfusionPerfusionNo (intracellular viral vectors)50,000--150,000 VP/cell 1.0 × 10^12^ rAd26 virus particles VP/mLRatio VP/IVP of 20:1Van and Luitjens [@CR61]A/PR/8/34 influenza (H1N1) virusMDCKAdherent6.2STRRepeated fed-batchRepeated fed-batchDiscontinuous13,630 VP/cell 5248 HA/100 μLCell-specific and volumetric yields higher than batchBock et al. [@CR2]A/PR/8/34 influenza virusHEK293Suspension6STR/acoustic settlerPerfusionPerfusionContinuous3960 VP/cellCell-specific yield increased fourfoldsPetiot et al. [@CR46]A/New Caledonia/20/99 influenza (H1N1) virusMDCKAdherent8Fixed bedRecirculationRecirculationNo, washout with PBS and medium exchange before infection2.89 log~10~ (HA units/100 μL) and 7.8 × 10^7^ TCID50/mLNovel disposable pack-bed bioreactorSun et al. [@CR58]A/PR/8/34 influenza (H1N1) virusCAPSuspension26.9STR/ATFPerfusionPerfusionNo4086 VP/cell 1.18 × 10^12^ VP/d LCell-specific and volumetric productivity comparable to batchGenzel et al. [@CR16]A/PR/8/34 influenza (H1N1) virusAGE1.CRSuspension28.1STR/ATFPerfusionPerfusionNo1708 VP/cell 7.0 × 10^11^ VP/d LCell-specific and volumetric productivity comparable to batchGenzel et al. [@CR16]A/PR/8/34 & A/Mexico/4108/2009 influenza (H1N1) virusMDCKAdherent/Suspension40/28Hollow fiberRecirculationPeriodic harvestDiscontinuousA/PR/8/34 (in suspension MDCK cells): 19,138 VP/cell 2.64 × 10^11^ VP/d A/Mexico/4108/2009 (in suspension MDCK cells): 3219 VP/cellCell-specific yields comparable to previous reports in batchTapia et al. [@CR59]Moloney murine leukemia virus (MoMLV) retrovirus vector293GPGSuspension11STR/Acoustic settlerPerfusionPerfusionContinuous3--4 107 IVP/mLTwentyfold increase in specific productivity compared to adherent cells. Cell line produces infective virus constitutively, no need of infectionGhani et al. [@CR17]*Parapoxvirus ovis*BKAdherent7STRPeriodic medium exchangeVolume expanded fed-batchNo1.06 × 10^8^ VP/LdTwentyfold increase in volumetric productivity, compared to batchPohlscheidt et al. [@CR48]Poliovirus (PV) type 1, 2 & 4VeroAdherent2STRSemi-batchFed-Batch (Glucose/Gln)No356 DU/mL (PV1)1.5- to 2-fold increase in cell-specific and volumetric yield compared to batchThomassen et al. [@CR60]RabiesVeroAdherent5STR/spin filterRecirculationPerfusionContinuous1.38 × 10^8^ FFU/mL2.6-fold higher specific productivity than batchRourou et al. [@CR53]*VP* total viral particles, *IVP* infective viral particles, *FFU* fluorescent focus units, *DU* D-antigen units, *HA* hemagglutinin

Process options to achieve high densities for adherent and suspension cells {#Sec3}
---------------------------------------------------------------------------

It is important to note that maximum cell concentrations that are typically achieved differ between adherent and suspension cells. Provided similar aeration conditions, the maximum number of adherent cells that can be obtained in bioreactors depends on the available growth surface, while the maximal growth of suspension cells is mainly limited by the total amount of nutrients in the growth medium and the accumulation of growth-inhibiting compounds. In addition, further limitations for HCD processes using suspension cells such as space, reactor design, and operation as well as aeration have to be considered as discussed previously (Ozturk [@CR45]). In particular, the addition of medium (fed-batch) or the exchange of medium (perfusion) is usually not sufficient for obtaining HCD with adherent cells, and an increase in growth surface, for example, by the addition of microcarriers in STRs, is required. The use of microcarriers offers the additional advantage that it allows an easy exchange of medium by sedimentation of carriers after switching off the stirrer of cultivation vessels or stopping the rocking unit of wave systems. For instance, an increase from 1.8 × 10^6^ cells/mL to 1.1 × 10^7^ cells/mL could be achieved for adherent Madin-Darby canine kidney (MDCK) cells when increasing the concentration of the microcarrier Cytodex 1 from 2.0 to 12.5 g/L using a repeated fed-batch process (Bock et al. [@CR2]). Medium exchange was performed based on an estimated cell-specific feeding rate (Dowd et al. [@CR10]). In another example, the proliferation of bovine kidney (BK) cells on Cytodex 3 for the propagation of *Parapoxvirus ovis* up to 7.0 × 10^6^ cells/mL was carried out using a periodic medium exchange (Pohlscheidt et al. [@CR48]) based on the minimum glucose concentration measured. Finally, a recirculation-based feeding mode was applied for the propagation of Vero cells grown on microcarriers at about 6.0 × 10^6^ cells/mL for subsequent infection with various poliovirus serotypes (Thomassen et al. [@CR60]). In this process, a fresh medium of an STR was circulated through the cultivation bioreactor at increasing rates depending on cultivation time.

Although similar to the recirculation strategy followed by Thomassen et al. ([@CR60]), a special case has been reported for the proliferation of both adherent and suspension MDCK cells in a single-used hollow fiber bioreactor for propagation of pandemic influenza virus (Tapia et al. [@CR59]). Here, cell concentrations of about 3.0 × 10^7^ cells/mL were obtained by recirculation of fresh medium through the hollow fibers providing nutrients to the cells and diluting accumulated toxic compounds.

Besides adherent cell lines, suspension cells are routinely grown to HCD using fed-batch (Xie and Wang [@CR70]) and perfusion-based feeding strategies (Kompala and Ozturk [@CR28]). For example, the use of perfusion systems in the production of adenoviral vectors has been described by Nadeau and Kamen ([@CR41]). However, cell concentrations did not exceed 6.0 × 10^6^ cells/mL and neither a significant change in volumetric yield nor in cell-specific yields was observed compared to batch cultivations. Since this application has been comprehensively described by Nadeau and Kamen ([@CR41]), it will not be addressed further in this review. More recently, external cell retention systems such as acoustic filters (Petiot et al. [@CR46]) or the ATF system (Genzel et al. [@CR16]) have been used in various vaccine production processes established in research laboratories. Using an acoustic filter, suspension HEK293 cells have been grown to concentrations approaching 6.0 × 10^6^ cells/mL before infection with a recombinant adenovirus type 5 (Henry et al. [@CR21]) and type A influenza virus (Petiot et al. [@CR46]), respectively. In this case, cell growth continued even after infection reaching 11 (Henry et al. [@CR21]) and 14 × 10^6^ cells/mL (Petiot et al. [@CR46]). In another study, the designer cell lines AGE1.CR and CAP have been cultivated to 4.8 and 3.3 × 10^7^ cells/mL, respectively, for the propagation of type A influenza virus (Genzel et al. [@CR16]; Villiger-Oberbek et al. [@CR67]) using an ATF system. Significant efforts have also been reported regarding options to intensify vaccine production processes using PER.C6 cells. Although this cell line can be cultivated up to 1.0 × 10^7^ cells/mL in batch (Sanders et al. [@CR55]) and above 1.0 × 10^8^ cells/mL in perfusion mode using an ATF system (Mercier et al. [@CR40]; Vellinga et al. [@CR66]), current production of adenoviral vectors (serotype 26 and 35) are carried out only at a PER.C6 cell concentration of about 1.6 × 10^7^ cells/mL (Van and Luitjens [@CR61]).

The theoretical maximum cell concentration, which can be obtained for animal cells, is considered to be about 10^9^ cells/mL (Ozturk [@CR45]). Given that the supply of cells with critical substrates and the removal of growth-inhibiting compounds can always be guaranteed by appropriate feeding and perfusion strategies, the maximum cell concentration largely depends on the volumetric oxygen transfer coefficient (k~L~a) that the cultivation system supports. Accordingly, depending on the cell line, the use of conventional stirred tank or wave bioreactors with k~L~a values up to 55 1/h should allow achieving cell densities in the order of 1 × 10^8^ cells/mL. As expected, experiments show that it is challenging to obtain such high concentration in these cultivation systems and that additional issues, such as accumulation of CO~2~ to toxic concentrations, have to be taken into account. For example, Clincke et al. ([@CR4]) have reported previously on CHO cell cultivations exceeding 2 × 10^8^ cells/mL, where a suitable aeration/agitation strategy combined with CO~2~-stripping needed to be implemented.

Process options to maintain high cell-specific virus yields {#Sec4}
-----------------------------------------------------------

To achieve high virus titers, cells should typically be infected during the late exponential growth phase. In addition, an optimal supply of nutrients at toi is required (Aunins [@CR1]). The latter can be achieved by a complete medium exchange prior to addition of the virus seed (Bock et al. [@CR2]; Pohlscheidt et al. [@CR48]) or by an intensive medium renewal during the cell proliferation phase (Thomassen et al. [@CR60]). The use of a perfusion rate of two reactor volumes per day starting immediately after virus infection also helped to improve adenovirus yields in HEK293 cells (Henry et al. [@CR20]). Here, losses of infectious virus particles in the clarified fraction at the early phase of infection were compensated by infecting with an moi two times higher (moi = 20) than in the reference process in batch (moi = 10).

In order to support virus propagation after virus addition, fed-batch mode and/or discontinuous medium exchange have been carried out, especially in processes based on immobilized cells. For example, infecting MCDK cells grown on Cytodex 1, Bock et al. ([@CR2]) demonstrated that performing a repeated fed-batch process during the first 2 to 10 h post infection allowed to obtain cell-specific influenza A virus yields threefolds higher compared to a conventional batch process. Similarly, Pohlscheidt et al. ([@CR48]) applied a so-called volume-expanded fed-batch strategy during propagation of a *P. ovis* strain in BK cells grown on Cytodex 3. This cultivation strategy consisted in the discontinuous addition of medium to a final volume four times larger than the initial operation volume. Here, total virus yield was increased 40-fold, while virus titers and volumetric productivity were increased in one and two orders of magnitude, respectively, in comparison to a batch process (Pohlscheidt et al. [@CR48]). Compared to a typical fed-batch process (with shorter volume additions), the volume-expanded fed-batch strategy resulted in an almost sixfold increase in total virus yield. Finally, daily harvesting of virus-containing supernatants in a hollow fiber system was reported to produce high titers of influenza A virus and cell-specific virus yields comparable to those obtained in the typical batch production mode in STR (Tapia et al. [@CR59]). This shows that this strategy can be suitable not only for the production of viruses that propagate exclusively in mitotic cells and have a long replication cycle, such as the mink enteritis virus (MEV) (Roya and Mehrad [@CR54]), but also for fast-propagating strains, e.g., influenza A virus.

When operating processes with suspension cell lines, continuous virus harvest/medium exchange is more feasible. In this regard, acoustic filters have been used for cell retention and harvesting of a cell-free virus broth. For example, influenza A virus produced in HEK293 cells was continuously harvested in the clarified supernatant with cell-specific yields of about 4000 virions per cell (Genzel et al. [@CR16]; Petiot et al. [@CR46]). Here, to avoid virus loss in the clarified fraction, medium exchange was not carried out for some hours after infection to allow for an efficient uptake of virions into cells. As addressed before, other commercially available separation systems used at industrial scale, e.g., gravity settlers or spin filters (Pollock et al. [@CR49]), could also allow for continuous virus harvests when infecting suspension cells at concentrations about 2 × 10^7^ cells/mL (Kompala and Ozturk [@CR28]). Furthermore, continuous virus harvests at cell concentrations in the order of 10^8^ could be also possible using new types of bioreactors such as the perfusion bioreactor CellTank®.

An alternative approach to perform virus propagation using perfusion systems is the retention of both cells and virus particles within the bioreactor. For the case of the ATF system mentioned before, it was shown that continuous medium exchange resulted in high cell-specific yields of influenza A virus at laboratory scale. However, the choice of a suitable hollow fiber membrane seems to be a crucial factor since the pore size of membranes seems to have an influence on productivity (Genzel et al. [@CR16]). It is evident that when using membrane-based separation systems, a sound characterization of cell retention during the growth phase must be carried out since any change in porosity and average pore size will have a negative impact on virus retention or harvest titers. Whether it is beneficial to continuously harvest virus particles or to retain them within the bioreactor during the whole virus production phase has to be determined in advance and characteristics of filtration modules have to be chosen accordingly. It might be even beneficial to consider the use of different pore sizes for both cell growth and virus production phases. Similar to acoustic filter-based processes (Genzel et al. [@CR16]; Petiot et al. [@CR46]), for ATF-based processes, a medium exchange should be avoided for few hours after addition of virus seeds to allow for an efficient uptake of virions into cells.

Although ATF and TFF systems share a similar separation principle, i.e., tangential flow filtration, TFF systems have not been used for virus production, so far. One possible reason might be the fact that cells are being exposed to a larger shear stress as TFF systems involve the use of peristaltic pumps (Nienow et al. [@CR42]). It can be expected, however, that improvements such as the implementation of low-stress pumping systems, e.g., magnetic levitated pumps, will promote the use of TFF systems.

Advantages and challenges of current HCD production processes {#Sec5}
-------------------------------------------------------------

Most of the recent approaches toward HCD cultivations in vaccine production have demonstrated that it is possible to maintain or even increase cell-specific virus yields. Given an accumulation of contaminating DNA and host cell proteins proportional to the concentration of cells, the impact on following downstream operations should not be adversely affected. In contrast, the concentration of clarified harvests that is typically performed prior to subsequent chromatography steps either needs only minor modification or, in the best-case scenario, is not required anymore. Furthermore, the use of perfusion systems and a continuous medium exchange during virus propagation phase can mitigate the accumulation of DNA and host cell proteins in the viral harvests. Accordingly, regarding the establishment of HCD cultivations, a negative impact on final product quality is not anticipated.

Nevertheless, there are still various productivity indicators and economic aspects that must be considered, before establishing industrial-scale applications. For example, based on the volumetric productivity (the total amount of virus particles produced per volume of culture medium consumed, virus particles/L), the so-called space time yield (STY, virus particles/(L h)) can be determined taking into account the complete production time. This performance indicator better reflects overall process costs than mere volumetric (virus particles/L) or cell-specific yields (virus particles/cell). This way, even processes with very high product concentration and high cell-specific yield compared to a batch process could be less productive given the large volumes of media consumed or the extended production time or both (Genzel et al. [@CR16]). Also, production process parameters at HCD could impact intrinsic properties, such as the glycosylation of viral proteins and the ratio of infectious virions to the total number of virions, which are key properties of both viral vaccines and viral vectors. Accordingly, small-scale studies addressing medium optimization for HCD cultivations, the establishment of medium feeding, cell cultivation and virus harvesting strategies, and the analysis of critical quality attributes of products are essential to promote the use of HCD processes in routine viral vaccine production.

Multi-stage bioreactors for continuous virus production {#Sec6}
=======================================================

The establishment of continuous cultures can be tracked back to the 1950s (Novick and Szilard [@CR43]), where it raised many questions and challenges in the production of biologicals. Finally, however, the focus was on the establishment of batch cultivations due to their advantages regarding ease of operation and process robustness. In addition, productivity increased significantly, as fast advances in genetic engineering were made (Hoskisson and Hobbs [@CR22]). With an ever increasing number of biologicals introduced into the market, however, the interest in more efficient manufacturing platforms is back and tackling several challenges for the next decades, such as the integration of upstream and downstream in fully continuous operated processes, will take a greater role (Warikoo et al. [@CR69]). Continuous production has several well-known advantages compared to the batch cultures, such as steady-state operation, high volumetric efficiency, and lower plant turndown that enhance process yield. Continuous production of many biologicals has been achieved with the use of STR operated in single (chemostat) or multi-stage STR configurations. The use of chemostats (Novick and Szilard [@CR43]) is suitable for molecular biology research or for simple cases, where cells are cultivated on a defined substrate, to obtain maximum biomass and/or high product yields (Málek and Fenel [@CR38]). Nevertheless, stable operation with chemostats can fail, when the product is produced in small amounts (Fencl et al. [@CR11]), when cell growth is inhibited by the product, or in case cell deteriorates as occuring, e.g., with lytic viruses. An alternative to chemostats is multi-stage systems, such as several STRs in series, or STRs in series with tubular bioreactors (Hu and Bentley [@CR23]; Málek and Fencl [@CR38]). One interesting approach for virus production is the use of two-stage STR bioreactors, as depicted in Fig. [2](#Fig2){ref-type="fig"}a. Here, the first reactor serves only for cell propagation and the subsequent bioreactor for virus infection and continuous virus replication (Frensing et al. [@CR13]). The addition of more STR in series (Fig. [2](#Fig2){ref-type="fig"}b) could potentially increase virus yields by approaching the residence time distribution of a plug-flow reactor or by increasing the RT of cells in the system, with virus release in the subsequent vessels (Gori [@CR18]; van Lier et al. [@CR62]). Therefore, in the following section, the use of multi-stage STR systems using cascades of two and three STR is addressed as an option for process intensification in viral vaccine production.Fig. 2Schematic representations of continuous multi-stage stirred tank reactor (STR) setups. **a** Scheme of a continuous two-stage STR system used for continuous influenza A virus production described by Frensing et al. ([@CR13]); **b** a multi-stage STR setup following a plug-flow-like configuration (Hu et al. [@CR24]; Málek and Fencl [@CR38]; van Lier et al. [@CR62]), in which a cascade of STR was used. As before, the first bioreactor (*n* = 1) is exclusively for cell propagation, while virus is produced in the subsequent vessels

Overview of two- and three-stage bioreactors used for continuous production of viruses {#Sec7}
--------------------------------------------------------------------------------------

Multi-stage systems have been used for propagation of bacteriophages in bacteria (Jacobson and Jacobson [@CR25]) as well as for replication of viruses in human cells (Gori [@CR18]), insect cells (Kompier et al. [@CR29]), and avian cells (Frensing et al. [@CR13]) (see Table [2](#Tab2){ref-type="table"}). Additional options for continuous viral vaccine production exist for processes using persistently infected cells, as reported for instance (Roumillat et al. [@CR52]; Roumillat et al. [@CR51]) for herpes simplex virus growth in lymphoblastoids. Eventually, semi-continuous virus production is also possible in cultures using adherent cells or in cultivation systems involving hollow fiber units. Shen et al. ([@CR57]), for instance, used multiple harvest strategies for retroviral production in a NIH 3T3 fibroblast-derived adherent amphotropic murine cell line (pMFG/ΨCRIP) for efficient retroviral production. However, as these options involve only one single stage, where the cell growth phase and the virus replication phase are taking place in the same compartment, they are not considered in this section. Accordingly, in Table [2](#Tab2){ref-type="table"}, only examples for continuous multi-stage production systems established at laboratory scale are summarized.Table 2List of viruses cultivated in continuous multi-stage bioreactorsVirusMulti-stage configuration^a^Cell lineCell originDuration (d p.i)^b^Max. virus titer (×10^7^ TCID50/mL)Mathematical modelPassage effect observed?CommentsReferencePoliovirus 1Two STR stagesHela S-3-1Human118.3YesNoFirst concepts and term "lysostat" introducedGori [@CR18]AdenovirusThree STR stagesHela-derived KB cell lineHuman6.51.0YesNoGori [@CR18]Baculovirus E2-strainTwo and three STR stagesSf-AE-21Insect301.0^d^YesYesEarlier passage effect in three-stage respect to two-stagevan Lier et al. [@CR62]Recombinant baculovirus---AcMNPVSemi-continuous repeated fed-batch (two STR stages)Sf-9Insect8010^c^YesYesPassage effect was delayed respect to continuousvan Lier et al. [@CR65]; De Gooijer et al. [@CR7]Foot-and-mouth disease virusSemi-continuous two STR stagesBHK21 C13Mammal181.6NoNoBioreactor sizes of 10 and 3 L for cell and virus production, respectivelyRoth et al. [@CR50]Recombinant baculovirus---vIBD-7STR followed by a tubular reactor (two-stage system)Sf-9Insect8Not reportedNoYesBaculovirus expressing β-galactosidaseHu et al. [@CR24]Recombinant baculovirus with extra homologous regions (hrs)Two STR stagesSe301Insect27100 cNoYesInsertion of an extra homologous region in the BAC vector led to prolonged protein expressionPijlman et al. [@CR47]Influenza A/PR/8/34 (RKI)Two STR stagesAGE1.CR.pIXAvian18700YesYesPassage effect led to low yieldsFrensing et al. [@CR13]^a^STR: stirred tank reactor^b^d p.i: days post infection^c^Titer of non-occluded viruses (NOVs) in TCID50 per milliliter^d^Units of polyhedra per cubic centimeter of reactor

Production of poliovirus and adenovirus {#Sec8}
---------------------------------------

The term "lysostat" was first used to describe a two-stage and three-stage bioreactor for cultivation of poliovirus 1 and adenovirus replicated in a Hela S-3-1 and a Hela-derived KB cell line, respectively (Gori [@CR18]). Poliovirus type 1 was grown with a yield of 421 TCID~50~ per cell and adenovirus type 14 with a yield of 116 TCID~50~ per cell. This pioneer work demonstrated clearly that a continuous production of viruses is possible and introduced a basic mathematical description of two and three continuous STR bioreactors for virus production. It also pointed out that special considerations have to be taken into account for thermolabile viruses. In particular, virus particles have to be removed from the STR with a dilution rate exceeding the specific virus inactivation rate. Furthermore, it is important to keep infected cells in the bioreactor until lysed (or until virus release ceases in case of non-lytic viruses). However, with a life cycle of 5 to 24 h as found for many viruses relevant in vaccine production, this might result in non-optimal steady state conditions and require specific measures to keep virus yields at a high level. Finally, cell concentrations at steady state have to be selected carefully to avoid substrate limitations or the accumulation of inhibiting by-products of metabolism or viral compounds.

Production of baculovirus {#Sec9}
-------------------------

A significant contribution using multi-stage bioreactors and the baculovirus-insect cell expression system was done by the group of Tramper and Vlak (Kompier et al. [@CR29]). In a first publication, two experiments using two-stage cultivation systems operated for 25 and 60 days were described that achieved steady-state production levels of polyhedra and non-occluded virus (NOV) particles for up to 25 days. In this work, for the first time, it was observed that a drop in virus titers is possible at advanced production times (35 days) in continuous mode. And it was suggested that this was due to a "passage effect" induced by DIPs (Krell [@CR32]). A first mathematical model that used a first-order reaction mechanism was introduced later (De Gooijer et al. [@CR6]) to describe baculovirus production in two- and three-stage cultivation systems. The model predicted well the time courses of the viable cell and the non-infected cell concentrations in the virus production bioreactor, but did not describe the passage effect. This last aspect was later covered with a structured model, where the effect of DIPs on virus titers of two- and three-stage STR bioreactors was considered explicitly (De Gooijer et al. [@CR7]). In another publication, a three-stage bioreactor setup (using two vessels for infection) was compared against a two-stage bioreactor system for baculovirus production (van Lier et al. [@CR62]). It was shown that the use of a three-stage bioreactor accelerated the occurrence of viruses with a higher virus passage number, which in turn resulted in an earlier drop in virus yield (passage effect) compared to two-stage cultivations. Thus, three-stage bioreactor setups seem to be disadvantageous for baculovirus production compared to two-stage bioreactor systems as a more plug-flow-like configuration seems to result in viruses with high passage number. In the following, more studies (Lier et al. [@CR34]; van Lier et al. [@CR63]) were carried out using a two-stage bioreactor system to produce a recombinant baculovirus containing the LacZ gene expressing β-galactosidase. For the first time, a DNA analysis showed the existence of a predominant mutant baculovirus that lacked about 40 % of the DNA genome, including the LacZ gene. This confirmed the presence of DIPs in continuous multi-stage baculovirus cultivations and their impact in process productivity. In addition, it allowed to develop hypotheses regarding possible mechanisms of DIP formation (Kool et al. [@CR31]). In another study, baculoviruses were genetically engineered to maintain expression levels (van Lier et al. [@CR64]). However, virus production still decreased after about 30 days of continuous operation. Finally, production in the two-stage reactor system was optimized by performing repeated semi-continuous infections, in which an inoculum of the previous infection was used as seed virus (van Lier et al. [@CR65]). This mode of operation led to an enhancement in performance, compared to continuously operated two-stage systems with regard to longer-term operation. In a more recent study (Pijlman et al. [@CR47]), stability of the virus was increased by the utilization of extra homologous repeat regions, which are located throughout the baculovirus genome and are believed to act as origins of viral DNA replication. This resulted in prolonged protein expression and improved the stability of baculovirus expression vectors for the large-scale protein production in insect-cell bioreactors.

Production of influenza virus {#Sec10}
-----------------------------

In a recent study carried out in our laboratory (Frensing et al. [@CR13]), influenza virus A/PR/8/34 (RKI) was continuously produced with the avian cell line AGE1.CR.pIX in a two-stage bioreactor setup operated continuously for 18 days. Virus titers similar to those of batch cultivations published by Lohr et al. ([@CR36]) were observed. Unfortunately, virus titers fluctuated over several orders of magnitude due to the presence of defective interfering particles (DIPs), which were confirmed by a PCR assay. A segregated mathematical model of the two-stage system suggested that constant virus titers can only be obtained in the absence of DIPs. Currently, different approaches using the avian suspension cell line AGE1.CR.pIX (Lohr et al. [@CR37]) as a substrate for virus replication are being evaluated in our laboratory to overcome this hurdle for continuous production of influenza virus.

Outlook on high cell density cultivations and continuous multi-stage bioreactors {#Sec11}
================================================================================

It is clear that a long way is still to be passed in vaccine manufacturing to reach the level of process intensification established for other biologicals, i.e., the production of recombinant proteins in CHO cells. Nevertheless, results achieved at the laboratory scale shed a very positive light regarding options for further optimization of large-scale viral vaccine production. Combining knowledge obtained for process intensification in the production of other cell culture-derived biologicals (i.e., the optimization of media, development of designer cell lines, introduction of fed-batch/continuous perfusion systems), advances in automation technologies (on-line monitoring/control of metabolites and cell concentration), and availability of technologies for establishing HCD under cGMP conditions (i.e., membrane-based perfusion systems and hollow fiber units) should allow to catch up fast with the increasing demands for potent and save vaccines at low costs. Continuous processes using multi-stage stirred tank bioreactor systems are also an interesting option to batch production of viruses. In particular, at laboratory scale, experiments have demonstrated that harvests with similar virus titers can be obtained, e.g., for influenza virus production. Duration of continuous processes, however, is clearly limited by the accumulation of DIPs in the population of many (if not most) DNA and RNA viruses. Unfortunately, the presence of DIPs can significantly reduce product titers, and this effect seems to stronger if the number of vessels in a cascade is increased. Thus, the use of two-stage stirred tank bioreactor systems seems to be the best option for intensification of viral vaccine production processes. Furthermore, multi-stage STR systems involving the use of three or more STRs in series would probably not be accepted in large-scale vaccine manufacturing due to the complexity of operation and the increasing risk of process failure. Furthermore, it has to be considered for both two-stage and multi-stage STRs that there is a higher risk of accumulating unwanted antigenic variations of virus strains due to extended process times. Accordingly, all steps towards process intensification have to be carefully evaluated with respect to their potential impact on the quality of the final product, i.e., safety and immunogenicity. Nevertheless, the implementation of HCD cultivations using fed-batch or perfusion strategies seems currently a very attractive option for process intensification. HCD cultivations have the potential to achieve cell concentrations exceeding 10^8^ cells/mL, and it has been shown by several research groups that the so-called cell density effect can be overcome for many viruses. Accordingly, it should be possible to improve productivity in vaccine manufacturing 10- to 100-fold compared to conventional batch cultivations. While it may take several years to translate these ideas into large-scale vaccine manufacturing, HCD cultivations, and for some viruses, cascades of continuous stirred tank bioreactors, are the most promising steps toward manufacturing of more efficacious, safe, and cost-effective viral vaccines.
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